Analysts Show High Confidence in Compass Therapeutics (CMPX) Following Progress with CTX-10726
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 01 2025
0mins
Should l Buy CMPX?
Source: Yahoo Finance
Investment Potential: Compass Therapeutics, Inc. (NASDAQ:CMPX) has been highlighted as a promising investment opportunity due to its strong performance and significant upside potential, with a "Buy" rating and a $24 price target from analyst Joseph Pantginis.
Pipeline Progress: The company's advancing pipeline, particularly the preclinical drug CTX-10726, shows substantial potential with impressive anti-tumor activity, positioning it competitively against existing treatments.
Financial Overview: Compass reported a cash balance of $220 million at the end of Q3 2025, which is expected to support operations through 2028, despite a net loss of $14.3 million for the quarter.
Future Expectations: The company anticipates delivering key survival data for its drug tovecimig in early 2026, which could lead to its first Biologics License Application (BLA) filing later that year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMPX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMPX
Wall Street analysts forecast CMPX stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.000
Low
8.00
Averages
12.67
High
24.00
Current: 6.000
Low
8.00
Averages
12.67
High
24.00
About CMPX
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rocket Lab and Compass Therapeutics Show Active Options Trading
- Rocket Lab Options Volume: Rocket Lab Corp's options trading volume reached 312,719 contracts today, representing approximately 31.3 million shares, which is 124.2% of its average daily trading volume over the past month, indicating strong market interest in its future performance.
- High Volume Call Options: Within Rocket Lab, the $80 strike call option has seen 23,187 contracts traded today, representing about 2.3 million shares, reflecting investor expectations for future price increases, particularly for contracts expiring in April 2026.
- Compass Therapeutics Options Activity: Compass Therapeutics Inc recorded an options trading volume of 27,391 contracts, equating to approximately 2.7 million shares, which is 109.2% of its average daily trading volume over the past month, showing sustained investor interest in the company.
- Surge in Call Options Trading: For Compass Therapeutics, the $10 strike call option has traded 10,982 contracts today, representing around 1.1 million shares, indicating market confidence in its growth potential, especially for contracts expiring in May 2026.
See More
Surge in Options Trading Volume for Alphabet and Compass Therapeutics
- Alphabet Options Volume: Alphabet Inc (GOOG) saw options trading volume of 166,517 contracts today, representing approximately 16.7 million shares, which is about 82.8% of its average daily trading volume of 20.1 million shares over the past month, indicating strong market interest in GOOG.
- High Volume Contracts: Notably, the $300 strike call option expiring on May 15, 2026, has seen 7,282 contracts traded today, representing approximately 728,200 underlying shares of GOOG, reflecting investor expectations for future price increases.
- Compass Options Activity: Compass Therapeutics Inc (CMPX) has recorded an options trading volume of 12,693 contracts today, equivalent to about 1.3 million shares, which constitutes 63.5% of its average daily trading volume of 2.0 million shares over the past month, showcasing active market engagement with CMPX.
- Bullish Call Contracts: The $6 strike call option expiring on April 17, 2026, has seen 12,247 contracts traded today, representing approximately 1.2 million underlying shares of CMPX, indicating optimistic sentiment among investors regarding the company's future performance.
See More
Compass Therapeutics Reports Q4 and Full Year 2025 Financial Results
- Financial Performance: Compass Therapeutics reported a Q4 GAAP EPS of -$0.09, with a net loss of $66.5 million for the year ending December 31, 2025, compared to $49.4 million in 2024, indicating ongoing challenges in profitability.
- R&D Expense Increase: R&D expenses rose to $56.0 million in 2025 from $42.3 million in 2024, a 32% increase primarily driven by $7.7 million in manufacturing costs related to tovecimig and $5.9 million for CTX-10726, reflecting the company's commitment to drug development.
- Administrative Cost Rise: General and administrative expenses increased to $16.9 million in 2025 from $15.1 million in 2024, a 12% rise, largely due to pre-commercialization expenses of $0.7 million and advisory fees of $0.5 million, indicating increased spending in market readiness.
- Cash Position: As of December 31, 2025, Compass had $209 million in cash and marketable securities, up from $127 million in 2024, with an expected cash runway into 2028, despite using $49 million in net cash for operating activities, offset by $129 million in net proceeds from a public offering.
See More
Analysis of Growth Drivers in the Biliary Tract Cancer Market
- Market Size Growth: The biliary tract cancer market is projected to reach $1.1 billion in 2024, with the U.S. accounting for approximately 60% of this market, indicating a strong demand for new therapies in this leading region.
- Emerging Drug Launches: The introduction of new drugs such as Tinengotinib and Rilvegostomig is expected to further drive market growth, particularly in the areas of targeted therapies and immuno-oncology, enhancing treatment options for patients.
- Advancements in Diagnostic Technology: Improvements in imaging techniques like MRI, endoscopic ultrasound, and PET have enhanced the accuracy of biliary tract cancer diagnoses, enabling earlier detection and personalized treatment approaches, thereby improving patient outcomes.
- Market Dynamics in Treatment: By 2034, chemotherapy is expected to remain the primary revenue source for biliary tract cancer treatment, and the introduction of new therapies will alter the competitive landscape, fostering medical innovation and economic growth.
See More
Palo Alto Investors Acquires Stake in Compass Therapeutics
- New Investment Activity: Palo Alto Investors LP initiated a new position in Compass Therapeutics by purchasing 2,532,419 shares in Q4 2025, amounting to an investment of $13.60 million, indicating strong confidence in the biotech firm.
- Position Analysis: This investment represents 1.89% of Palo Alto Investors LP's assets under management, highlighting the firm's significant interest in Compass, which may influence future investment strategies.
- Stock Performance: As of February 17, 2026, Compass Therapeutics shares were priced at $6.39, reflecting a remarkable 101.58% increase over the past year, significantly outperforming the S&P 500 by 77.14 percentage points, showcasing market recognition of its growth potential.
- Company Overview: Compass Therapeutics focuses on developing antibody therapeutics targeting cancer and tumor vascularization, and as it advances through clinical trials, successful product approvals and partnerships are expected to generate substantial revenue potential for the company.
See More
Oncolytics Biotech Appoints New Executives to Accelerate Cancer Treatment Progress
- Market Potential: The global immuno-oncology market is projected to surge from $35 billion to $185.69 billion, reflecting strong demand for coordinated immune system activation, attracting capital influx and driving the precision medicine market to $537.17 billion.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy, which will enhance the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: Pelareorep achieved a 29% objective response rate in third-line treatment, nearly tripling historical benchmarks, with a median duration of response reaching 17 months, indicating potential for accelerated approval in a setting with no FDA-approved options.
- FDA Design Approval: Oncolytics secured FDA alignment on its Phase 3 study design for first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease, further solidifying its leadership in the oncology immunotherapy space.
See More
Rocket Lab and Compass Therapeutics Show Active Options Trading
- Rocket Lab Options Volume: Rocket Lab Corp's options trading volume reached 312,719 contracts today, representing approximately 31.3 million shares, which is 124.2% of its average daily trading volume over the past month, indicating strong market interest in its future performance.
- High Volume Call Options: Within Rocket Lab, the $80 strike call option has seen 23,187 contracts traded today, representing about 2.3 million shares, reflecting investor expectations for future price increases, particularly for contracts expiring in April 2026.
- Compass Therapeutics Options Activity: Compass Therapeutics Inc recorded an options trading volume of 27,391 contracts, equating to approximately 2.7 million shares, which is 109.2% of its average daily trading volume over the past month, showing sustained investor interest in the company.
- Surge in Call Options Trading: For Compass Therapeutics, the $10 strike call option has traded 10,982 contracts today, representing around 1.1 million shares, indicating market confidence in its growth potential, especially for contracts expiring in May 2026.
See More
Surge in Options Trading Volume for Alphabet and Compass Therapeutics
- Alphabet Options Volume: Alphabet Inc (GOOG) saw options trading volume of 166,517 contracts today, representing approximately 16.7 million shares, which is about 82.8% of its average daily trading volume of 20.1 million shares over the past month, indicating strong market interest in GOOG.
- High Volume Contracts: Notably, the $300 strike call option expiring on May 15, 2026, has seen 7,282 contracts traded today, representing approximately 728,200 underlying shares of GOOG, reflecting investor expectations for future price increases.
- Compass Options Activity: Compass Therapeutics Inc (CMPX) has recorded an options trading volume of 12,693 contracts today, equivalent to about 1.3 million shares, which constitutes 63.5% of its average daily trading volume of 2.0 million shares over the past month, showcasing active market engagement with CMPX.
- Bullish Call Contracts: The $6 strike call option expiring on April 17, 2026, has seen 12,247 contracts traded today, representing approximately 1.2 million underlying shares of CMPX, indicating optimistic sentiment among investors regarding the company's future performance.
See More
Compass Therapeutics Reports Q4 and Full Year 2025 Financial Results
- Financial Performance: Compass Therapeutics reported a Q4 GAAP EPS of -$0.09, with a net loss of $66.5 million for the year ending December 31, 2025, compared to $49.4 million in 2024, indicating ongoing challenges in profitability.
- R&D Expense Increase: R&D expenses rose to $56.0 million in 2025 from $42.3 million in 2024, a 32% increase primarily driven by $7.7 million in manufacturing costs related to tovecimig and $5.9 million for CTX-10726, reflecting the company's commitment to drug development.
- Administrative Cost Rise: General and administrative expenses increased to $16.9 million in 2025 from $15.1 million in 2024, a 12% rise, largely due to pre-commercialization expenses of $0.7 million and advisory fees of $0.5 million, indicating increased spending in market readiness.
- Cash Position: As of December 31, 2025, Compass had $209 million in cash and marketable securities, up from $127 million in 2024, with an expected cash runway into 2028, despite using $49 million in net cash for operating activities, offset by $129 million in net proceeds from a public offering.
See More
Analysis of Growth Drivers in the Biliary Tract Cancer Market
- Market Size Growth: The biliary tract cancer market is projected to reach $1.1 billion in 2024, with the U.S. accounting for approximately 60% of this market, indicating a strong demand for new therapies in this leading region.
- Emerging Drug Launches: The introduction of new drugs such as Tinengotinib and Rilvegostomig is expected to further drive market growth, particularly in the areas of targeted therapies and immuno-oncology, enhancing treatment options for patients.
- Advancements in Diagnostic Technology: Improvements in imaging techniques like MRI, endoscopic ultrasound, and PET have enhanced the accuracy of biliary tract cancer diagnoses, enabling earlier detection and personalized treatment approaches, thereby improving patient outcomes.
- Market Dynamics in Treatment: By 2034, chemotherapy is expected to remain the primary revenue source for biliary tract cancer treatment, and the introduction of new therapies will alter the competitive landscape, fostering medical innovation and economic growth.
See More
Palo Alto Investors Acquires Stake in Compass Therapeutics
- New Investment Activity: Palo Alto Investors LP initiated a new position in Compass Therapeutics by purchasing 2,532,419 shares in Q4 2025, amounting to an investment of $13.60 million, indicating strong confidence in the biotech firm.
- Position Analysis: This investment represents 1.89% of Palo Alto Investors LP's assets under management, highlighting the firm's significant interest in Compass, which may influence future investment strategies.
- Stock Performance: As of February 17, 2026, Compass Therapeutics shares were priced at $6.39, reflecting a remarkable 101.58% increase over the past year, significantly outperforming the S&P 500 by 77.14 percentage points, showcasing market recognition of its growth potential.
- Company Overview: Compass Therapeutics focuses on developing antibody therapeutics targeting cancer and tumor vascularization, and as it advances through clinical trials, successful product approvals and partnerships are expected to generate substantial revenue potential for the company.
See More
Oncolytics Biotech Appoints New Executives to Accelerate Cancer Treatment Progress
- Market Potential: The global immuno-oncology market is projected to surge from $35 billion to $185.69 billion, reflecting strong demand for coordinated immune system activation, attracting capital influx and driving the precision medicine market to $537.17 billion.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy, which will enhance the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: Pelareorep achieved a 29% objective response rate in third-line treatment, nearly tripling historical benchmarks, with a median duration of response reaching 17 months, indicating potential for accelerated approval in a setting with no FDA-approved options.
- FDA Design Approval: Oncolytics secured FDA alignment on its Phase 3 study design for first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease, further solidifying its leadership in the oncology immunotherapy space.
See More
